Skip to main content

🚀 Company objectives

2024 objetive​

Invoice 💶​

  • Objective: Increase revenue by 2.5X (250%) compared to the previous year, reaching €870,369.
  • Achievement: Closed the year with €410,787, reflecting a 117.99% growth over the previous year.
    • Result: Achieved 47% of the revenue target.

Review the invoce by segment section for more information

New markets 🌍​

  • Objective: Expand into two new markets.
  • Achievement: Successfully entered three markets: Germany, Brazil, and Hong Kong.
    • Result: Achieved 150% of the goal, exceeding expectations.
    • Current Global Presence: Operations in Spain, France, Germany, Sweden, Hong Kong, Brazil, and the United States.
      • In the US, presence is indirect, facilitated by a clinical trial in collaboration with Almirall.
  • Key Wins:
    • Closed 8 new contracts.
    • Secured the first public tender with SESPA.

NPS 💜​

Objective: Improve NPS from 60% to 70%.

  • Achievement: Achieved an NPS of 73%, surpassing the goal.
    • Result: Exceeded the target by 3 percentage points, reflecting enhanced customer satisfaction and loyalty.
Important

These objectives have been affected by the lack of a business development team and the founding team's focus on compliance audits and the financing round. This has caused us to move much slower than expected and led to delays in closing contracts.

2025 objetives​

Thanks to the funding secured in 2024, we focused on recruiting and training to build a strong business development team. This year, we expect to move much faster in sales. In 2024, we successfully entered new markets and progressed in key agreements; in 2025, our goal is to finalize those deals and consolidate our presence in these markets.

Invoice 💶​

3.5X (350%) 1,437,755€

New Markets 🌍​

2 new markets.

Regulatory Certification​

  • FDA approval
  • ANVISA approval

Improve customer satisfaction metrics 💜​

  • Customer satisfaction score (CSAT) > 75% measured quarterly and at the end of each clinical study
  • Clinical utility score (CUS) > 70% measured every six months and at the end of each clinical study